{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-079575","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.129811+00:00","generated_at":"2026-06-26T21:51:23.345406+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Arrowhead shareholders reject advisory pay plan and director comp plan at annual meeting","bullets":["Advisory vote on executive compensation: 54.8M against vs 14.2M for; proposal fails.","Non-Employee Director Compensation Plan: 52.5M against vs 16.0M for; proposal fails.","Three directors (Ferrari, Perry, Waddill) received majority AGAINST votes (44.4M, 39.8M, 42.7M resp.).","Ratification of auditors (Rose Snyder & Jacobs) passed with 87.2M votes for.","Approx. 20.2M broker non-votes on all proposals except auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-079575","json":"https://secwatch.observer/filing/0001193125-22-079575.json","markdown":"https://secwatch.observer/filing/0001193125-22-079575.md","text":"https://secwatch.observer/filing/0001193125-22-079575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000119312522079575/0001193125-22-079575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000119312522079575/d321053d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:51:23.345406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}